Table 1 Characteristics of eligible trials for general sarcoma with chemotherapy based treatment for phase I and phase II
Author | Year | Intervention | No Osteo patients | No Ewing Patients | Phase | Outcome |
|---|---|---|---|---|---|---|
Pratt et al, Cancer, 74: 2593-8 [22] | 1994 | Leucovorin, 5-Fluorouracil | 22 | 12 | II | Ewing: 3 (25%) SD, Osteo: 1 (5%) SD |
Kushner et al, J Clin Oncol, 13 (11): 2796-804 [23] | 1995 | Cyclo, Doxo, Etop, Ifos, Vin | Not mentioned | Not mentioned | II | 6 (17%) CR, 2 (6%) PR, 34 (95%) CIR |
Antman et al, Cancer, 82 (7): 1288-95 [24] | 1998 | Doxo, Dacarbazine, Ifos | 31 | 13 | II | 10 (12%) CR, 34 (42%) PR |
Blaney et al, Clin Cancer Res, 4 (2): 357-60 [25] | 1998 | Topotecan | 18 | 25 | II | 1 (1%) CR, 1 (1%) PR, 8 (9%) SD |
Lucidarme et al, Bone Marrow Transplant, 22 (6): 535-40 [26] | 1998 | Thiotepa combined with SCR | 7 | 3 | II | 11 (50%) PR |
Berg et al, J Pediatric Hematol Oncol, 22 (6): 506-9 [27] | 2000 | Pyrazoloacridine | 8 | 10 | II | 0% response |
Delaloge et al, J Clin Oncol, 19 (5): 1248-55 [28] | 2001 | Trabectedin | 3 | 1 | I | 4 (14%) CR, 10 (35%) SD |
Saylors et al, J Clin Oncol, 19 (15): 3463-9 [29] | 2001 | Cyclo and Topotecan | 18 | 17 | II | 6 (35%) OR |
Wagner et al, Clin Cancer Res, 10 (3): 840-8 [30] | 2004 | Temozolomide, Irinotecan | 0 | 7 | I | 1 (8%) CR, 2 (17%) PR |
Lau et al, Clin Cancer Res, 11: 672-7 [31] | 2005 | Trabectedin | 4 | 3 | I | 1 (8%) CR |
van Winkle et al, Pediatr Blood Cancer, 44 (4): 338-47 [32] | 2005 | Ifos, Carboplatin and Etop | 35 | 22 | I/II | Not mentioned |
Hawkins et al, Pediatr Blood Cancer, 47 (6): 328-37 [33] | 2006 | Topotecan | 11 | 20 | II | 2 (4%) PR |
Navid et al, Cancer, 106 (8): 1846-56 [34] | 2006 | Vin, Doxo, Cyclo, Ifos and Etop | 0 | 11 | II | 47 (66%) CR |
Wagner-Bohn et al, Cancer, 46 (2): 262 [35] | 2006 | Gemcitabine | 2 | 4 | II | 2 (10%) SD |
Zaucha et al, Int J Rad Oncol Biol Phys, 64 (1): 227-34 [36] | 2006 | Total body radiation after high-dose chemotherapy | 0 | 10 | II | 13 (25%) CR, 10 (19%) PR |
Zwerdling et al, Cancer, 106 (8): 1821-8 [37] | 2006 | Docetaxel | 23 | 21 | II | 2 (1%) CR, 6 (3%) PR, 17 (10%) SD |
Geoerger et al, J Clin Oncol, 26: 4394-400 [38] | 2008 | Oxaliplatin | 6 | 2 | I | 2 (4%) PR, 17 (6%) SD |
Geler et al, Pediatr Blood Cancer, 52 | 2009 | Paclitaxel, Ifos | 1 | 3 | I | 3 (20%) PD, 5 (33%) SD |
Wagner et al, ASCO abstract | 2009 | Vin, Irinotecan, Temozolomide | 3 | 5 | I | 1 (3%) PR,2 (6%) OR |
McGregor et al, Cancer, 115 (8): 1765-75 [39] | 2009 | Oxaliplatin, Irinotecan | 6 | 1 | I | 1 (8%) CR, 1 (8%) SD |